title: T(2)-weighted microMRI and evoked potential of the visual system measurements during the development of hypomyelinated transgenic mice.
abstract: Our objective was to follow the course of a dysmyelinating disease followed by partial recovery in transgenic mice using non-invasive high-resolution (117 x 117 x 70 microm) magnetic resonance (microMRI) and evoked potential of the visual system (VEP) techniques. We used JOE (for J37 golli overexpressing) transgenic mice engineered to overexpress golli J37, a product of the Golli-mbp gene complex, specifically in oligodendrocytes. Individual JOE transgenics and their unaffected siblings were followed from 21 until 75-days-old using non-invasive in vivo VEPs and 3D T2-weighted microMRI on an 11.7 T scanner, performing what we believe is the first longitudinal study of its kind. The microMRI data indicated clear, global hypomyelination during the period of peak myelination (21-42 days), which was partially corrected at later ages (>60 days) in the JOE mice compared to controls. These microMRI data correlated well with [Campagnoni AT (1995) "Molecular biology of myelination". In: Ransom B, Kettenmann H (eds) Neuroglia--a Treatise. Oxford University Press, London, pp 555-570] myelin staining, [Campagnoni AT, Macklin WB (1988) Cellular and molecular aspects of myelin protein gene-expression. Mol Neurobiol 2:41-89] a transient intention tremor during the peak period of myelination, which abated at later ages, and [Lees MB, Brostoff SW (1984) Proteins in myelin. In: Morell (ed) Myelin. Plenum Press, New York and London, pp 197-224] VEPs which all indicated a significant delay of CNS myelin development and persistent hypomyelination in JOE mice. Overall these non-invasive techniques are capable of spatially resolving the increase in myelination in the normally developing and developmentally delayed mouse brain.
authors.affiliation: Department of Physics, University of Winnipeg, 515 Portage Avenue, Winnipeg, Manitoba, Canada, R3B 2E9. m.martin@uwinnipeg.ca
authors.forename: Melanie
authors.initials: M
authors.lastname: Martin
authors.forename: Samuel D
authors.initials: SD
authors.lastname: Reyes
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Hiltner
authors.forename: M Irene
authors.initials: MI
authors.lastname: Givogri
authors.forename: J Michael
authors.initials: JM
authors.lastname: Tyszka
authors.forename: Robin
authors.initials: R
authors.lastname: Fisher
authors.forename: Anthony T
authors.initials: AT
authors.lastname: Campagnoni
authors.forename: Scott E
authors.initials: SE
authors.lastname: Fraser
authors.forename: Russell E
authors.initials: RE
authors.lastname: Jacobs
authors.forename: Carol
authors.initials: C
authors.lastname: Readhead
mesh_terms: D000818:Animals; D001921:Brain / Q000254:growth & development; D002493:Central Nervous System Diseases / Q000503:physiopathology; D005074:Evoked Potentials, Visual / Q000502:physiology*; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D051379:Mice; D008818:Mice, Neurologic Mutants; D008822:Mice, Transgenic; D004676:Myelin Basic Protein / Q000172:deficiency*; D009419:Nerve Tissue Proteins / Q000502:physiology; D014157:Transcription Factors / Q000502:physiology
chemical_list: C499047:Mbp protein, mouse; D004676:Myelin Basic Protein; D009419:Nerve Tissue Proteins; D014157:Transcription Factors